Determining the Survival Rate in Children with ALL in the Northeast of Iran via Competing Risks Approach
- سال انتشار: 1399
- محل انتشار: مجله سرطان خاورمیانه، دوره: 11، شماره: 3
- کد COI اختصاصی: JR_MISJ-11-3_012
- زبان مقاله: انگلیسی
- تعداد مشاهده: 183
نویسندگان
Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Physiotherapy Research Center, Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Laboratory Hematology and Blood Banking Blood, Tehran, Iran
Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pediatrics Hematology and Oncology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Background: We designed this study to assess the significant prognostic factors of both recurrence and death in patients with acute lymphoblastic leukemia in a university-based hospital using a parametric competing risks model. Methods: In this retrospective study, we included ۴۱۷ patients with acute lymphoblastic leukemia. Staining of bone marrow smears with Giemsa method confirmed the diagnosis, justifying at least ۲۵% lymphoblast. Treatment of patients was based on the Berlin-Frankfurt-Münster (BFM) protocol. We considered the first recurrence of cancer as the event of interest and non-relapse mortality as a competing risk. The employed two-parameter Weibull model accounted for both the interest and the competing events. Results: The relapse-free survival and the five-year overall mortality rates of patients were ۸۵.۹% and ۷۴%, respectively. The majority of the patients (۷۲.۷%) did not experience any event during the study period. We explained these events as first recurrence and non-relapse mortality, which occurred in ۴۴ (۱۰.۶%) and ۷۰ (۱۶.۸%) of the patients in the given order. The cumulative incident probability of the first recurrence and non-relapse mortality, were ۱۳.۴۳% and ۱۸.۶۱%, respectively. Conclusion: Based on the model, we identified white blood cell count and central nervous system involvement as important prognostic factors in determining the incidence rate. Therefore, they must be considered in the selection of treatment plan and risk stratification.کلیدواژه ها
Survival analysis, Acute Lymphoblastic Leukemia, Parametric competing risks model, Cumulative incidence probabilityاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.